Otsuka Pharmaceutical Co. and H. Lundbeck A/S Feb. 28 announced that the Food and Drug Administration has approved Abilify Maintena (aripiprazole) extended-release injectable suspension for the treatment of schizophrenia.
The companies said Abilify Maintena is the first dopamine D2 partial agonist approved as a once-monthly injection. Abilify already is approved in tablet and oral solution formulas.
Abilify Maintena will be the first commercialized product from the long-term global alliance between Otsuka and H. Lundbeck to develop central nervous system medicines worldwide. In November 2011, Japan-based Otsuka and Denmark-based H. Lundbeck announced the formation of an alliance to collaborate on the ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.